Eisai's Halaven approved for breast cancer

FDA approved an NDA from Eisai Co. Ltd. (Tokyo:4523; Osaka:4523) for Halaven eribulin to treat metastatic breast cancer in patients previously treated with at least two chemotherapy regimens for late-...